Article

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer

2020-03-23

Abstract excerpt

<title>Abstract</title> <p>Abstract Background While epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert a breakthrough effect, the incidence of skin disorders as a side effect has significantly reduced patients’ quality of life. Objective This study aimed to develop a treatment for inflammatory ulcers as one of the side effects of afatinib (Geotrif®), a second-generation EGFR-TKI, and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 37df2ea8-0800-53e8-94c4-50c3fcbe1158
DOI: 10.21203/rs.2.20607/v3

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancerDOI 10.21203/rs.2.20607/v3Read

Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.Semantic proximity Read

MSCs helped reduce scarring in the cornea after fungal infection when combined with anti-fungal treatmentSemantic proximity Read

Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.Semantic proximity Read

Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.Semantic proximity Read

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.Semantic proximity Read

A critical role of AREG for bleomycin-induced skin fibrosisSemantic proximity Read

Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.Semantic proximity Read

Anti-inflammatory and anti-fibrotic effects of topical pan-JAK inhibitor in a chronic graft-versus- host disease model mouseSemantic proximity Read

Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.Semantic proximity Read

Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer.Semantic proximity Read

Cefradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of T-LAK cell-originated protein kinaseSemantic proximity Read

The treatment of Tofacitinib for rosacea through the inhibition of the JAK/STAT signaling pathwaySemantic proximity Read